CND Life Sciences continues to build its presence as an exciting medical technology start-up. Phoenix Business Journal published a profile of the company this week along with the news of its freshly completed $2.4 million seed funding round.
Dr. Todd Levine Talks With Medical World News About the Potential of the Syn-One Test™ to Impact Patients’ Care
Todd Levine, MD, Co-Founder and Chief Medical Officer of CND Life Sciences was recently interviewed on Medical World News about the development of the Syn-One Test, how it can lead to better clinical decision making, and its potential to significantly impact the lives of patients with Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure, and multiple system atrophy.
Rick Morello spoke with Kevin Price, host of the Price of Business Radio Show, about how the Syn-One Test™ is advancing the way that neurodegenerative diseases like Parkinson’s disease and dementia with Lewy bodies are diagnosed.
News of CND Life Sciences’ $2.4 million grant from the National Institutes of Health is generating interest in news outlets for both healthcare professionals and patients.
Hiring slowed in the healthcare sector across the Valley during the coronavirus pandemic, but that trend is starting to reverse course, fueled in part by growing businesses such as CND Life Sciences.
Drs. Christopher Gibbons and Roy Freeman–two of the founders of CND Life Sciences who also serve as senior medical advisors–recently had their research on orthostatic hypotension as an early sign of Parkinson’s disease and dementia highlighted in a New York Times article.